Embattled FDA official defends vaccine plan in closed-door remarks
Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing…
Tracy Beth Høeg will lead FDA Center for Drug Evaluation and Research
WASHINGTON — Tracy Beth Høeg, a top lieutenant to Food and Drug Administration Commissioner Marty Makary, will be…
Top FDA regulator accused of using office to settle personal vendetta
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
George Tidmarsh, Uniqure, Pfizer, Metsera: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
FDA approves Blenrep, a GSK blood cancer drug with unusual history
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Summit Therapeutics hits possible snag on lung cancer drug seen as blockbuster
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Readout Newsletter: FDA, Paxil, chikungunya, GSK
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Viking Therapeutics oral weight loss drug hits mark in mid-stage trial
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and…
Ultrasound could deliver drugs with fewer side effects
After testing different types and concentrations of sugars, the researchers found that 5% sucrose added to the liquid…
New Novartis ESC data highlights strength of cardiovascular portfolio
PRESS RELEASE Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol…
Eli Lilly’s much-anticipated obesity pill falls short of Wegovy
Eli Lilly’s investigational obesity pill led to less weight loss in a late-stage trial than the reductions seen…
Sarepta Therapeutics’ Elevidys faces ‘arduous’ path back to market
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…